Table 2.
Prognostic characteristics and treatments of men with prostate cancer by number of PSA testing received from 2000 to 2005 prior to diagnosis; SEER-Medicare database. (n=22,047)
| Cancer Characteristics | Number of PSA screening tests from 2000 to 2005* | ||||
|---|---|---|---|---|---|
| Never (n = 1446) | 1 (n = 3692) | 2 (n = 3362) | 3 (n = 3530 ) | 4 to 6 (n = 10017) | |
| Median PSA (95% Confidence Interval), ug/mL | 11.9 | 12.9 | 9.0 | 7.5 | 7.2 |
| (10.9, 13) | (12.3, 13.6) | (8.7, 9.3) | (7.2, 7.7) | (7.0, 7.3) | |
| Gleason Score, % | |||||
| Gleason 2–4 | 16 (1) | 31 (1) | 36 (1) | 33 (1) | 98 (1) |
| Gleason 5–6 | 424 (29) | 988 (27) | 1166 (35) | 1336 (38) | 4358 (44) |
| Gleason 7 | 452 (31) | 1329 (36) | 1237 (37) | 1295 (37) | 3565 (36) |
| Gleason 8–10 | 371 (26) | 1080 (30) | 774 (23) | 766 (22) | 1772 (18) |
| Unknown | 183 (13) | 264 (7) | 149 (4) | 100 (3) | 224 (2) |
| Stage, % | |||||
| T1 | 573 (40) | 1384 (38) | 1465 (44) | 1571 (45) | 4880 (49) |
| T2 | 626 (43) | 1765 (48) | 1581 (47) | 1686 (48) | 4599 (46) |
| T3/T4 | 110 (8) | 266 (7) | 165 (5) | 141 (4) | 252 (3) |
| Unknown | 137 (9) | 277 (8) | 151 (4) | 128 (4) | 286 (3) |
| Risk group, % | |||||
| Low | 279 (19) | 617 (17) | 801 (24) | 1109 (29) | 3171 (32) |
| Intermediate | 496 (34) | 1292 (35) | 1362 (41) | 1434 (41) | 4325 (43) |
| High | 671 (46) | 1786 (48) | 1199 (36) | 1087 (31) | 2521 (25) |
| Treatment in 180 days, % | |||||
| Conservative Management | 716 (50) | 954(26) | 842 (25) | 859 (24) | 2282 (23) |
| Radical Prostatectomy | 74 (5) | 238 (6) | 270 (8) | 310 (9) | 984 (10) |
| Radiation Therapy | 457 (32) | 1291 (35) | 1352 (40) | 1536 (44) | 4742 (47) |
| Hormone Therapy | 199 (14) | 1209 (33) | 898 (27) | 825 (23) | 2009 (20) |
*
Difference across number of PSA tests received prior to diagnosis were statistically significant (p<.001) for all characteristics.